About This Calculator
The Insulin Degludec Dose Calculator provides dosing recommendations for healthcare professionals based on established clinical guidelines. It assists in determining the appropriate starting dose, switching from other insulins, or titrating an existing dose for patients with Type 1 or Type 2 diabetes. This tool is for informational purposes and does not replace clinical judgment.
Understanding the Outputs
The calculator provides a recommended dose and a clinical rationale based on the inputs provided. Key outputs include:
- Initiation Dose: For insulin-naïve patients with Type 2 diabetes, a standard starting dose of 10 units once daily is recommended. For Type 1 diabetes, the calculation is based on total daily insulin dose (TDID) estimates, typically using a percentage of body weight.
- Switching Dose: When converting from other basal insulins, the tool suggests a 1:1 unit conversion for once-daily regimens (e.g., glargine U-100) and a 20% dose reduction for twice-daily NPH insulin to mitigate hypoglycemia risk.
- Titration Adjustment: Based on the average fasting blood glucose (FBG), the tool recommends a specific unit adjustment (e.g., +2 units, -4 units) to help patients achieve glycemic targets.
How to Use the Calculator
To obtain a dosing recommendation, follow these steps:
- Select Patient Type: Choose whether the patient has Type 1 or Type 2 diabetes.
- Choose Calculation Scenario:
- Select Initiate Therapy for patients new to insulin.
- Select Switch Insulin for patients converting from another insulin product.
- Select Titrate Dose for patients already on insulin degludec who require a dose adjustment.
- Enter Patient Data: Input the required values, such as patient weight, previous insulin regimen and total daily dose, or current dose and average fasting blood glucose.
- Calculate: The tool will generate a recommended dose and provide context for the decision.
Dosing Overview
Insulin degludec is a long-acting basal insulin administered once daily, at any time of day. Dosing should be individualized based on the patient's metabolic needs, blood glucose monitoring results, and glycemic goals.
- Type 2 Diabetes (Insulin-Naïve): The recommended starting dose is 10 units once daily.
- Type 1 Diabetes: Insulin degludec should be used in a regimen with short- or rapid-acting mealtime insulin. The starting dose is typically calculated as a fraction (e.g., one-third to one-half) of the estimated total daily insulin requirement.
- Titration: Dose adjustments are generally made once or twice weekly based on self-monitored fasting plasma glucose levels until the glycemic target is reached.
Switching to Insulin Degludec
When transitioning patients to insulin degludec, careful dose selection is crucial to ensure safety and efficacy.
- From Once-Daily Basal Insulin: Patients can be transferred on a unit-to-unit basis from other once-daily basal insulins (e.g., insulin glargine U-100, insulin detemir) at the same dose.
- From Twice-Daily NPH Insulin: The recommended starting dose of insulin degludec is 80% of the total daily NPH dose. This reduction helps lower the risk of nocturnal hypoglycemia.
- From Pre-Mixed Insulin: Conversion requires careful clinical evaluation. The basal component of the pre-mixed insulin must be identified, and mealtime insulin coverage must be appropriately replaced. Close glucose monitoring is essential during the transition.
Missed Dose Protocol
Due to its ultra-long duration of action, there is some flexibility if a dose is missed. Patients should be advised to take their missed dose as soon as they remember. It is important to ensure there are at least 8 hours between injections. Patients should not take a double dose to make up for a missed one and should resume their regular once-daily dosing schedule thereafter.
Safety Alerts
Hypoglycemia: This is the most common adverse reaction associated with all insulin products, including insulin degludec. Dose adjustments, changes in meal patterns, physical activity, and co-administered medications can affect the risk. Patients should be educated on recognizing and managing hypoglycemia.
Monitoring: Regular blood glucose monitoring is essential for all patients, especially during initiation, titration, and periods of illness or stress.
Professional Judgment: This tool is not a replacement for professional clinical judgment. Dosing decisions must be tailored to the individual patient's needs, lifestyle, and clinical picture. Always consult the full prescribing information.
Frequently Asked Questions
Why is the starting dose for Type 2 Diabetes fixed at 10 units?
A starting dose of 10 units once daily is the recommended approach for most insulin-naïve patients with Type 2 diabetes, as established in clinical trials and prescribing information. This provides a safe and effective starting point, which is then titrated based on individual glucose response.
Why does the calculator require weight for Type 1 but not Type 2 initiation?
For Type 1 diabetes, the total daily insulin dose (TDID) is often estimated based on body weight (e.g., 0.4-1.0 units/kg/day). The initial basal dose is a percentage of this TDID. For Type 2, the standard 10-unit starting dose is used regardless of weight, simplifying initiation.
What is the logic behind the 20% dose reduction when switching from NPH insulin?
Insulin degludec has a more stable and prolonged pharmacokinetic profile compared to NPH insulin, which has a more pronounced peak. Reducing the total daily dose by 20% upon switching is a conservative strategy to minimize the risk of hypoglycemia, particularly overnight.
How does the titration calculator adjust for high FBG?
The tool uses a common titration algorithm. For FBG levels moderately above target (e.g., 140-180 mg/dL), it suggests a small increase of 2 units. For significantly high levels (e.g., >180 mg/dL), it recommends a larger increase of 4 units to achieve control more quickly.
What should I do if a patient's FBG is below 80 mg/dL?
The calculator recommends a dose reduction to prevent hypoglycemia. The standard recommendation is to decrease the dose by the greater of 2 units or 10% of the current dose. This approach provides a meaningful reduction while being proportional to the patient's existing insulin sensitivity.
Can I switch from Insulin Glargine U-300 (Toujeo) at a 1:1 ratio?
While the calculator specifies a 1:1 switch from once-daily basals like glargine U-100, switching from concentrated insulins like glargine U-300 may require a dose reduction (e.g., 20%) due to differences in potency and duration. This requires clinical judgment and is not explicitly covered by the simple scenarios in this tool.
Why does the tool state "clinical judgment" for switching from pre-mixed insulin?
Pre-mixed insulins contain both a basal and a prandial (mealtime) component. A simple conversion is not possible. A clinician must separate these components, start insulin degludec at an appropriate dose (often 80-100% of the previous basal component), and initiate a separate mealtime insulin regimen.
How often should I use the titration feature?
Dose adjustments for insulin degludec are typically made every 3-4 days to allow the drug to reach a steady state. The FBG value entered into the calculator should be an average of at least three recent measurements to ensure the adjustment is based on a stable trend.
References
- 1. TRESIBA® (insulin degludec) injection [Prescribing Information]. Plainsboro, NJ: Novo Nordisk Inc. Available at: https://www.novo-pi.com/tresiba.pdf
- 2. U.S. Food and Drug Administration (FDA). Drugs@FDA: TRESIBA (insulin degludec). Accessed from: FDA.gov
- 3. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S140-S157. doi:10.2337/dc23-S009
- 4. Novo Nordisk. Tresiba® (insulin degludec injection) Dosing & Administration Guide for HCPs. Accessed from: TresibaPro.com
- 5. European Medicines Agency (EMA). Tresiba (insulin degludec) Summary of Product Characteristics (SmPC). Accessed from: EMA.europa.eu
